Plain language summary of publication: new information for the potential role of afatinib in treating people with NRG1 gene fusion-positive cancer
This plain language summary reports the findings of a case series, a study which evaluated a small number of people who had a certain type of cancer. This case series looked at how well a drug called afatinib worked in people who have a rare type of cancer called neuregulin-1 (also called NRG1) gene fusion-positive cancer.
Read the article in full here.
Click here to read the original article on which this summary is based.